Get the Stockscreener App
1.305
1.88%
-0.025
Hoth Therapeutics Inc stock is traded at $1.305, with a volume of 131.41K.
It is down -1.88% in the last 24 hours and up +6.97% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.33
Open:
$1.29
24h Volume:
131.41K
Relative Volume:
0.12
Market Cap:
$17.24M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.9886
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+1.95%
1M Performance:
+6.97%
6M Performance:
+3.57%
1Y Performance:
+89.13%
1-Day Range:
$1.2605
$1.335
1-Week Range:
$1.21
$1.41
52-Week Range:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.305 | 17.57M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
How many analysts rate Hoth Therapeutics Inc. as a “Buy”Earnings Report Growth Plan For Smart Trading - jammulinksnews.com
What are the latest earnings results for Hoth Therapeutics Inc.Wealth Building Picks That Work - jammulinksnews.com
What makes Hoth Therapeutics Inc. stock price move sharplyBest Dividend Data Feed To Watch Now - jammulinksnews.com
Hoth Therapeutics Engages ICON to Expand Clinical Trial for HT-001 - Contract Pharma
Hoth Therapeutics Inc. Flashes Rebound Signal in Oversold ConditionInvestment Strategy Designed for Capital Protection - metal.it
Hoth Therapeutics to expand phase II trial of HT-001 to EU countries - Investing.com
Cancer Treatment Breakthrough: Hoth Therapeutics Takes Phase II Trial Global with Major EU Expansion - Stock Titan
What is the dividend policy of Hoth Therapeutics Inc. stockDaily Trading Forecasts From AI Tools - jammulinksnews.com
Published on: 2025-07-28 20:31:38 - metal.it
What is the risk reward ratio of investing in Hoth Therapeutics Inc. stockInvest smarter with expert trading signals - jammulinksnews.com
What catalysts could drive Hoth Therapeutics Inc. stock higher in 2025Maximize portfolio growth with strategic plans - jammulinksnews.com
When is Hoth Therapeutics Inc. stock expected to show significant growthDynamic portfolio growth - jammulinksnews.com
How strong is Hoth Therapeutics Inc. company’s balance sheetSuperior trading gains - jammulinksnews.com
What institutional investors are buying Hoth Therapeutics Inc. stockFind market-beating stocks for your portfolio - jammulinksnews.com
Why is Hoth Therapeutics Inc. stock attracting strong analyst attentionGrow your wealth steadily and securely - jammulinksnews.com
What analysts say about Hoth Therapeutics Inc. stockFree Wealth Management Insights - Autocar Professional
What drives Hoth Therapeutics Inc. stock priceFree Trading Strategy Suggestions - Autocar Professional
Is Hoth Therapeutics Inc. a good long term investmentTriple returns potential - PrintWeekIndia
Traumatic Brain Injury Clinical, Companies, Therapeutic - openPR.com
Hoth Therapeutics Inc. Stock Analysis and ForecastHigh-yield trading alerts - Autocar Professional
Hoth Therapeutics shares fall 1.52% intraday after signing VA research deal to advance GDNF as breakthrough therapy for obesity and fatty liver. - AInvest
Hoth Therapeutics partners with VA to test GDNF therapy for obesity - Investing.com Nigeria
Hoth Therapeutics partners with VA to test GDNF therapy for obesity By Investing.com - Investing.com South Africa
New Weight Loss Drug Challenger GDNF Takes On Semaglutide in Landmark VA Obesity Study - Stock Titan
Why Hoth Therapeutics Inc. stock attracts strong analyst attentionElite Investor Club - Newser
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):